Literature DB >> 31192151

Unique Case of a Large Indolent Medullary Thyroid Carcinoma: Time to Reconsider the Medullary Thyroid Adenoma Entity?

Simona Censi1, Elisabetta Cavedon2, Sara Watutantrige-Fernando1, Susi Barollo1, Loris Bertazza1, Jacopo Manso1, Maurizio Iacobone3, Davide Nacamulli1, Francesca Galuppini4, Gianmaria Pennelli4, Caterina Mian1.   

Abstract

BACKGROUND: Medullary thyroid carcinoma (MTC) is a rare neuroendocrine cancer originating from parafollicular, calcitonin (Ctn)-producing C-cells. Prognosis correlates with primary tumor stage and Ctn levels. PATIENT: We describe a case of MTC involving a mass 7 cm in its largest dimension, associated with high Ctn concentrations (> 5,000 pg/mL), but normal carcinoembryonic antigen levels, and with no lymph nodes or distant metastases, in complete remission after thyroid surgery. The MTC had very peculiar histological features, with an expansive, noninfiltrating growth around the thyroid follicles, and no signs of invasion. These histopathological characteristics are reminiscent of the C-cell adenoma described in animals. The tumor also revealed an ossifying extracellular matrix unlike the classical amyloid. Despite the size of the tumor and the patient's high Ctn levels at diagnosis, the case described here reached complete remission after surgery.
CONCLUSIONS: Further studies are needed to clarify the characteristics of MTC and better predict its behavior at diagnosis.

Entities:  

Keywords:  Calcitonin; Carcinoembryonic antigen; Medullary thyroid cancer

Year:  2018        PMID: 31192151      PMCID: PMC6514480          DOI: 10.1159/000494675

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  14 in total

1.  Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970.

Authors:  H Gharib; W M McConahey; R D Tiegs; E J Bergstralh; J R Goellner; C S Grant; J A van Heerden; G W Sizemore; I D Hay
Journal:  Mayo Clin Proc       Date:  1992-10       Impact factor: 7.616

Review 2.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

3.  Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection.

Authors:  J F Moley; M K DeBenedetti
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

4.  Biomarker-based risk stratification for previously untreated medullary thyroid cancer.

Authors:  Andreas Machens; Henning Dralle
Journal:  J Clin Endocrinol Metab       Date:  2010-03-25       Impact factor: 5.958

5.  Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma.

Authors:  Daisy V Alapat; Kenneth B Ain; David A Sloan; Kristin G Monaghan; Rouzan G Karabakhtsian
Journal:  Endocrine       Date:  2011-01-18       Impact factor: 3.633

Review 6.  Medullary thyroid carcinoma.

Authors:  Sophie Leboulleux; Eric Baudin; Jean-Paul Travagli; Martin Schlumberger
Journal:  Clin Endocrinol (Oxf)       Date:  2004-09       Impact factor: 3.478

7.  Non-functional C-cell adenoma in aged horses.

Authors:  H Ueki; Y Kowatari; T Oyamada; M Oikawa; H Yoshikawa
Journal:  J Comp Pathol       Date:  2004 Aug-Oct       Impact factor: 1.311

8.  Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

Authors:  Rossella Elisei; Barbara Cosci; Cristina Romei; Valeria Bottici; Giulia Renzini; Eleonora Molinaro; Laura Agate; Agnese Vivaldi; Pinuccia Faviana; Fulvio Basolo; Paolo Miccoli; Piero Berti; Furio Pacini; Aldo Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

9.  Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer.

Authors:  Paolo Miccoli; Michele N Minuto; Clara Ugolini; Eleonora Molinaro; Fulvio Basolo; Piero Berti; Aldo Pinchera; Rossella Elisei
Journal:  Endocr Relat Cancer       Date:  2007-12       Impact factor: 5.678

10.  Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging.

Authors:  G Pellegriti; S Leboulleux; E Baudin; N Bellon; C Scollo; J P Travagli; M Schlumberger
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

View more
  2 in total

Review 1.  Is Encapsulated Medullary Thyroid Carcinoma Associated With a Better Prognosis? A Case Series and a Review of the Literature.

Authors:  Andrea Contarino; Alessia Dolci; Marco Maggioni; Francesca Maria Porta; Gianluca Lopez; Uberta Verga; Francesca Marta Elli; Elisabetta Francesca Iofrida; Gianmaria Cantoni; Giovanna Mantovani; Maura Arosio
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-27       Impact factor: 6.055

2.  Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study.

Authors:  Louise Vølund Larsen; Delphine Mirebeau-Prunier; Tsuneo Imai; Cristina Alvarez-Escola; Kornelia Hasse-Lazar; Simona Censi; Luciana A Castroneves; Akihiro Sakurai; Minoru Kihara; Kiyomi Horiuchi; Véronique Dorine Barbu; Francoise Borson-Chazot; Anne-Paule Gimenez-Roqueplo; Pascal Pigny; Stephane Pinson; Nelson Wohllk; Charis Eng; Berna Imge Aydogan; Dhananjaya Saranath; Sarka Dvorakova; Frederic Castinetti; Attila Patocs; Damijan Bergant; Thera P Links; Mariola Peczkowska; Ana O Hoff; Caterina Mian; Trisha Dwight; Barbara Jarzab; Hartmut P H Neumann; Mercedes Robledo; Shinya Uchino; Anne Barlier; Christian Godballe; Jes Sloth Mathiesen
Journal:  Endocr Connect       Date:  2020-06       Impact factor: 3.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.